Clene Inc.
CLNNAbout the company
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.
Investment snapshot
Positive
0
BUY / PASS
Neutral / negative
2 / 14
NEUTRAL / FAIL
Median fair value
—
No comparable estimates
Models with upside
0 / 17
Positive margin of safety
Key risk
No clean pass — all 16 investors flag at least one profitability criterion
Framework analysis
| Verdict | Meaning |
|---|---|
| BUY | Positive purchase signal: the framework's buy requirements are met. |
| PASS | The company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state. |
| NEUTRAL | Neither a positive nor negative conclusion. It does not mean to hold an existing position. |
| FAIL | The company does not clear the framework's requirements. |
| Ranked | Ranked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL. |
Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.
| Metric | Graham Defensive Value | Buffett Quality Compounder | Lynch GARP | Greenblatt Magic Formula | Piotroski F-Score | Dreman Contrarian Value | Munger Quality Focus | Pabrai Dhandho Framework | Akre Three-Legged Stool | Marks Risk-Aware Value | Ackman Activist Value | Templeton Global Bargain Hunter | Sleep Scale Economies Shared | Asness Systematic Factors | Neff Low-P/E Total Return | Schloss Asset-Value Discipline | O'Shaughnessy Systematic Factor Composite |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verdict | FAIL | FAIL | FAIL | Not ranked | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | FAIL | NEUTRAL | FAIL | FAIL | NEUTRAL |
| Score | |||||||||||||||||
| Analysis | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… | Checking access… |
| Intrinsic Value (annual) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Margin of Safety | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financial Basis | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Qualitative assessment · Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-17 Score computed: 2026-11-14 | Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 · Qualitative assessment Latest source filing: 2026-03-17 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | Annual history · FY 2025 Latest source filing: 2026-03-17 Score computed: 2026-11-14 | Annual history · FY 2025 · Balance sheet at 2026-09-30 Latest source filing: 2026-11-04 Score computed: 2026-11-14 | TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 Latest source filing: 2026-11-04 Score computed: 2026-11-14 |
Where It Passes
Where It Falls Short
- Profitability0% pass✓ 1✗ 34▾
No clean pass — all 16 investors flag at least one profitability criterion
Positive EPS (10 years)0/8 years positive✗GrahamPositive EPS every year for 10 yearsEPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthNet Income Positive (10+ years)0/8 years positive✗BuffettPositive every year for 10+ yearsROE (up to 5-year arithmetic mean)-1756.1%✗Buffett> 15% arithmetic mean (app rule)Operating Margin (10-yr trend)-11541.5% (latest)✗BuffettStable or rising over 10 yearsFree Cash Flow Proxy✗BuffettPositive and growingEarnings Variance (10-yr CoV)✗BuffettCoV < 0.3Retained Earnings Effectiveness✗Buffett$1 retained -> > $1 market value createdBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passROEN/A (negative equity)✗Lynch> 15%EBIT / Enterprise Value-38.3%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-38.3%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Net Income / Total Assets-144.35%✗PiotroskiROA > 0ROA Change YoY-144.13% -> -144.35% (delta: -0.23%)✗PiotroskiCurrent ROA > Prior ROA(CFO / Total Assets) vs ROACFO/Assets=-102.29%, ROA=-144.35%✓PiotroskiCFO/Assets > ROAGross Margin Change YoY79.5% -> 78.5%✗PiotroskiImproved YoYPre-Tax Income / Revenue-11271.4%✗Dreman>= 8%Net Income / Shareholders' Equity✗Dreman> 12%Margin of Safety✗PabraiP/B < 1.5 or P/E < 15Return on Equity-457.1% (3-yr avg)✗AkreROE > 20% (3-year avg)Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePositive Net Income Frequency0/7 years positive✗MarksPositive net income in >= 7 of last 10 yearsOperating Income / Revenue-8928.6%✗Ackman>= 15%Net Income / Shareholders Equity✗Ackman>= 15%5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Operating Margin Trend-6198.8% (2023) -> -11541.5% (2025)✗TempletonNon-negative operating-margin trend over 3 yearsRevenue growth vs. gross and operating margin trendgross margin 81.5% -> 78.5%, operating margin -6198.8% -> -11541.5%✗SleepRevenue rising; gross margin flat or falling; operating margin holdingNet income / market capitalization-47.52%; #5028/6340 (top 79.3%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionGross profit / total assets+0.87%; #3360/3702 (top 90.8%)✗AsnessTop 30% of eligible cross-sectionNet income / positive book equity✗AsnessTop 30% of eligible cross-sectionNegative 5-year standard deviation of ROA-0.4885; #4921/5884 (top 83.6%)✗AsnessTop 30% of eligible cross-section3-5 Year Diluted EPS CAGR✗Neff7%-20% annualizedPositive Diluted-EPS Years✗Schloss>= 70% positive over 5-10 observed years (app rule) - Debt & Leverage0% pass✗ 15▾
All 12 investors flag CLNN's debt & leverage
LT Debt vs Net Current AssetsLT Debt $17.5M vs NCA $-2.6M✗GrahamLT Debt <= Net Current AssetsDebt/Equity & Interest CoverageD/E: N/A (negative equity), IC: -7.3x✗BuffettD/E < 0.5 AND Interest Coverage > 5xTotal Debt / EquityN/A (negative equity)✗Lynch< 0.33Cash - Long-term Debt$-7.6M✗LynchPositive preferredLT Debt / Total Assets Change0.00% -> 98.10%✗PiotroskiDecreased YoYCurrent Assets / Current Liabilities0.85✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)Total Debt / Shareholders' Equity✗Dreman< 0.8✗Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✗SchlossD/E < 1.00xDebt LevelsN/A (non-positive equity)✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3Interest Coverage & Debt/EBITDAIC=-8.6x, D/EBITDA=N/A (D&A unavailable)✗MarksInterest Coverage > 3x; Debt/EBITDA < 4xTotal Debt / Shareholders Equity✗Ackman<= 1.0Negative debt-to-equity (higher means less debt)✗AsnessTop 30% of eligible cross-section - Valuation0% pass✗ 28▾
All 13 investors flag CLNN's valuation
Price / 3-yr avg EPS✗Graham<= 15xPrice-to-Book Ratio✗Graham<= 1.5xP/E x P/B✗Graham<= 22.5Basic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)EBIT / Enterprise Value-38.3%✗Greenblatt> 10%Earnings Yield + ROC AssessmentEY=-38.3%, ROC=N/A (invested capital <= 0)✗GreenblattBoth EY > 10% and ROC > 25%Price / EPS✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)Price / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xPrice / Book Value per ShareN/A (negative BVPS)✗Dreman< 1.2x✗Templeton< 1.5x✗SchlossP/B <= 0.80x (app cutoff)Valuation Reasonableness✗MungerP/E < 25 or Owner Earnings Yield > 5%P/E or FCF YieldFCF Yield=-32.9%✗PabraiP/E < 15 or FCF Yield > 10%P/B or P/E vs. Historical Average✗MarksP/E < 15 or P/B < 2.0Discount to Intrinsic Value✗Marks>= 20% below intrinsic valuePrice / FCF per ShareN/A (negative FCF)✗Ackman<= 25Price vs. Trailing Low132% of trailing low ($2.97)✗Templeton<= 120% of trailing low (certified split-adjusted live window)Net income / market capitalization-47.52%; #5028/6340 (top 79.3%)✗AsnessTop 30% of eligible cross-section✗OshaughnessyTop 10% of eligible cross-sectionPositive book equity / market capitalization-0.2623; #5853/6449 (top 90.8%)✗AsnessTop 30% of eligible cross-sectionPrice / Diluted EPS✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)(EPS CAGR % + Dividend Yield %) / P/E✗Neff> 0.7 (Neff's published traditional edge)Price / Tangible Book Value per ShareN/A (non-positive TBVPS)✗SchlossP/TBV <= 1.00x (app cutoff)Book Value per Share Change✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)Revenue / market capitalization+0.0042; #4939/5247 (top 94.1%)✗OshaughnessyTop 10% of eligible cross-section(Operating cash flow - capex) / market capitalization-32.92%; #3697/4519 (top 81.8%)✗OshaughnessyTop 10% of eligible cross-sectionTrailing six-month price return through the evaluation date-35.84%; #4661/6202 (top 75.2%)✗OshaughnessyTop 10% of eligible cross-section - Cash Flow0% pass✓ 1✗ 11▾
No clean pass — all 10 investors flag at least one cash flow criterion
Free Cash Flow Proxy✗BuffettPositive and growingFCF Positive and Growing$-18.6M✗LynchPositive and growingOperating Cash Flow$-18.5M✗PiotroskiCFO > 0(CFO / Total Assets) vs ROACFO/Assets=-102.29%, ROA=-144.35%✓PiotroskiCFO/Assets > ROAPrice / (CFO / Shares)N/A (negative CFPS)✗Dreman< 8xP/E or FCF YieldFCF Yield=-32.9%✗PabraiP/E < 15 or FCF Yield > 10%FCF Positive0/7 years FCF positive✗MarksPositive FCF in majority of recent years(OCF - CapEx) / Market Cap-43.7%✗Ackman>= 4%Price / FCF per ShareN/A (negative FCF)✗Ackman<= 25Positive Operating Cash Flow frequency0/7 years positive✗SleepPositive OCF in >= 70% of available yearsOperating Cash Flow - Capital Expenditures$-18.6M✗Neff> $0 (app proxy for a strong fundamental case)(Operating cash flow - capex) / market capitalization-32.92%; #3697/4519 (top 81.8%)✗OshaughnessyTop 10% of eligible cross-section - Growth0% pass✓ 1✗ 12▾
No clean pass — all 8 investors flag at least one growth criterion
EPS Growth (3-yr avg, 10-yr window)✗Graham>= 33% growthBasic earnings-growth PEG (dividends excluded)✗Lynch< 1.0 (ideally < 0.5)3-5 Year EPS CAGR✗Lynch15-30% (Fast Grower); > 0% to passInventory Growth vs Revenue GrowthInv: -32.8% vs Rev: 11.2%✓LynchInventory growth < Revenue growthEPS Growth Direction✗DremanPositive over recent yearsEPS CAGR✗Dreman> 5% annualizedPositive Net Income Frequency0/7 years positive✗MarksPositive net income in >= 7 of last 10 years3yr Median Revenue Growth-41.5%✗Ackman>= 5%Positive EPS Growth Frequency✗AckmanPositive EPS growth in >= 3 of last 5 years5-Year EPS CAGR✗Templeton> 0% (5-year EPS CAGR)Revenue growth vs. gross and operating margin trendgross margin 81.5% -> 78.5%, operating margin -6198.8% -> -11541.5%✗SleepRevenue rising; gross margin flat or falling; operating margin holding5-year Revenue CAGR-0.6%✗SleepCAGR > 7%3-5 Year Diluted EPS CAGR✗Neff7%-20% annualized - Efficiency0% pass✗ 11▾
All 8 investors flag CLNN's efficiency
Current Ratio0.85✗Graham>= 2.0ROIC (3-5 yr avg)-2731.9%✗Buffett> 10%ROIC - WACC-2741.9%✗BuffettPositive (WACC = 10%)EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)✗Greenblatt> 25%Current Ratio Change YoY1.57 -> 0.83✗PiotroskiIncreased YoYRevenue / Total Assets Change YoY0.01x -> 0.01x✗PiotroskiImproved YoYCurrent Assets / Current Liabilities0.85✗Dreman> 1.5Return on Invested CapitalN/A (non-positive invested capital)✗Munger> 15%ROIC (high and growing)FY2023: ROIC=-96.2%; FY2024: ROIC=-1127.8%; FY2025: ROIC=unavailable✗AkreLatest 3 consecutive FYs: ROIC > 15% in eachReinvestment Rate x ROIC✗AkreReinvestment Rate * ROIC > 10%ROIC (5-year)0/4 years above 12% (latest -1127.8%)✗SleepROIC > 12% in a majority of years - Verdicts0% pass✗ 14▾
Split decision: 14 FAIL · 2 NEUTRAL
Overall verdict✗GrahamFAIL (0/9)✗BuffettFAIL (0/9)✗LynchFAIL (1/7)•GreenblattNot ranked✗PiotroskiFAIL (F-Score 1)✗DremanFAIL (0/11)✗MungerFAIL (0/4)✗PabraiFAIL (0/3)✗AkreFAIL (0/6)✗MarksFAIL (0/5)✗AckmanFAIL (1/9)✗TempletonFAIL (1/8)✗SleepFAIL (0/6)•AsnessNEUTRAL (Not ranked)✗NeffFAIL (0/6)✗SchlossFAIL (0/7)•OshaughnessyNEUTRAL (Not ranked)
Business & financials
Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.
Company Profile
Financial Snapshot
Shareholder Return
Fiscal 2025
Issued 34.1% of shares last year.
- Buybacks
- —
- Dividends
- —
Company Financials
Latest TTM and quarters alongside annual years
TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.
The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.
| Metric | TTM · 2026-09-30 2025-10-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: revenue, net income, operating income, ebit, pre tax income, interest expense, operating cash flow, capex. | Q3 FY 2026 2026-07-01 – 2026-09-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow, capex. | Q2 FY 2026 2026-04-01 – 2026-06-30 Sources · derived quarter valuesDerived from cumulative filings: operating cash flow. | Q1 FY 2026 2026-01-01 – 2026-03-31 Sources | FY 2025Sources
| FY 2024Sources
| FY 2023Sources
| FY 2022Sources
| FY 2021Sources
|
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $56.4Mcurrent | -- | -- | -- | $44.4Mest. | $36.3Mest. | -- | $2.3Best. | $3.5Best. |
| Revenue | $238.0K↑11% | $56.0K↑273% | $90.0K↑233% | $15.0K↓81% | $200.0K↓42% | $342.0K↓48% | $654.0K↑38% | $473.0K↓35% | $723.0K |
| Operating Income | -$21.3M↑12% | -$6.3M↓12% | -$5.3M↑9% | -$2.1M↑49% | -$23.1M↑30% | -$33.1M↑18% | -$40.5M↑16% | -$48.4M↑3% | -$50.0M |
| Net Income | -$26.8M↑12% | $3.9M↑145% | -$13.4M↓81% | -$8.1M↓977% | -$26.2M↑34% | -$39.4M↑20% | -$49.5M↓65% | -$29.9M↓207% | -$9.7M |
| EPS (Diluted) | -- | $0.05 | -- | -- | -- | -- | -- | -- | $-0.16 |
| Gross Margin | — | — | — | — | 78.5%↓1% | 79.5%↓2% | 81.5%↓14% | 94.5%↑57% | 60.0% |
| Operating Margin | -8928.6%↑21% | -11333.9%↑70% | -5941.1%↑73% | -13740.0%↓173% | -11541.5%↓19% | -9676.3%↓56% | -6198.8%↑39% | -10234.5%↓48% | -6912.6% |
| ROE | 181.2%↓27% | — | — | — | 148.8%↓67% | 444.8%↑220% | -369.7%↑60% | -924.3%↓1095% | -77.3% |
| Total Debt | $8.9M↑74% | $8.9M↑74% | $5.4M↓67% | $5.5M↑9% | $6.1M↓45% | $11.2M↓44% | $19.9M↑25% | $15.9M↑10% | $14.5M |
| Shareholders' Equity | -$14.8M↓20% | -$14.8M↓20% | -$24.8M↓190% | -$18.8M↓278% | -$17.6M↓99% | -$8.9M↓166% | $13.4M↑314% | $3.2M↓74% | $12.6M |
| Current Ratio | 0.85↓44% | 0.85↓44% | 3.07↑94% | 1.94↑42% | 0.83↓47% | 1.57↑2% | 1.53↓27% | 2.11↓77% | 9.06 |
| Debt / Equity | -0.60↓45% | -0.60↓45% | -0.22↑89% | -0.29↑71% | -0.35↑72% | -1.26↓185% | 1.49↓70% | 4.91↑327% | 1.15 |
| Operating Cash Flow | -$16.5M↑11% | -$4.6M↓16% | -$2.6M↑45% | -$4.5M↑10% | -$18.5M↑13% | -$21.3M↑29% | -$30.2M↑23% | -$39.0M↓13% | -$34.6M |
| Free Cash Flow | -- | -$4.7M↓17% | -- | -- | -$18.6M↑13% | -$21.3M↑30% | -$30.5M↑31% | -$44.2M↓23% | -$36.0M |
Score history
Historical Score Timeline
Industry peers
Industry Peers
Similar companies in Pharmaceutical Products
CLNN vs Peers — Financial Grading
| Company | Market Cap | Price | Revenue | Net Income | ROE | D/E | Op. Margin | Curr. Ratio | Graham | Buffett | Lynch | Greenblatt | Piotroski | Dreman |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck & Co., Inc.MRK | $364.3B | $147.76 | $65.0B | $18.3B | 34.7% | 0.94 | — | 1.54 | 2/9 | 5/9 | 4/7 | 0/3 | F-Score 4 | 1/11 |
| ABBOTT LABORATORIESABT | $188.0B | $108.52 | $44.3B | $6.5B | 12.5% | 0.25 | 18.2% | 1.58 | 3/9 | 4/9 | 2/7 | 1/3 | F-Score 5 | 3/11 |
| BRISTOL MYERS SQUIBB COBMY | $129.7B | $63.43 | $48.2B | $7.1B | 38.2% | 2.44 | 19.4% | 1.26 | 2/9 | 1/9 | 3/7 | 1/3 | F-Score 8 | 5/11 |
| BIO-TECHNE CorpTECH | $11.4B | $72.80 | $1.2B | $73.4M | 3.8% | — | 8.4% | 3.46 | 4/9 | 3/9 | 3/7 | 0/3 | F-Score 5 | 4/11 |
| REPLIGEN CORPRGEN | $10.7B | $167.79 | $738.3M | $48.9M | 2.3% | 0.26 | 7.5% | 8.37 | 3/9 | 2/9 | 3/7 | 0/3 | F-Score 7 | 5/11 |
| IONIS PHARMACEUTICALS INCIONS | $4.8B | $29.06 | $943.7M | $381.4M | -78.0% | 3.60 | -40.4% | 3.83 | 3/9 | 1/9 | 1/7 | 0/3 | F-Score 4 | 3/11 |
| NEOGEN CORPNEOG | $2.5B | $11.23 | $870.4M | $7.9M | -0.4% | 0.76 | -2.5% | 3.82 | 3/9 | 1/9 | 2/7 | 0/3 | F-Score 6 | 4/11 |
| Pharvaris N.V.PHVS | $2.4B | $33.36 | — | $206.4M | -64.8% | 0.00 | — | — | 0/9 | 0/9 | 2/7 | 0/3 | F-Score 2 | 2/11 |